

The role of inflammatory processes in the etiopathogenesis of schizophrenia

Krzysztof Rudkowski, Jerzy Samochowiec, Aleksandra Mazur,
Jolanta Kucharska-Mazur

Abstract

In recent years, there has been a growing number of studies trying to explain the role of inflammatory processes in the pathogenesis of mental disorders, including schizophrenia. Epidemiological evidence supports the hypothesis of maternal immune activation during pregnancy, which increases the risk of schizophrenia in the offspring. Studies searching for potential biomarkers for schizophrenia suggest its links with pro-inflammatory cytokines. The process is also linked with complement cascade proteins and microglia cells, although the precise biological underpinnings still remain unclear. Importantly, several clinical trials provide evidence that certain anti-inflammatory substances have a beneficial effect on the treatment of schizophrenia. A better understanding of the role of inflammatory processes in the pathogenesis of schizophrenia will enable new solutions in preventive and therapeutic interventions. This paper aims to summarize current evidence on the potential biological mechanisms linking inflammatory processes to the etiopathogenesis of schizophrenia.

schizophrenia; psychosis; inflammation

INTRODUCTION

Schizophrenia is a complex mental illness, affecting perception, cognition, emotions and motivation of about 1% of the world's population [1]. In view of the expected increase in life expectancy, it can be assumed that the number of patients with schizophrenia is likely to double by 2030 and even triple by 2050 [2]. Delusions, hallucinations, disorganized thinking and cognitive dysfunction are listed as major components of its clinical presentation. The condition itself involves significant functional impairment as well as high socioeconomic burden. Suicide

rates among affected patient populations reach 10-15% [3]. Significant discoveries related to early recognition, early intervention and pharmacological stabilization of the mental state of patients have substantially improved not only the prognosis, but also the conduct of further, more extensive research in this area.

Schizophrenia is likely the most frequently and widely investigated neuropsychiatric disease. Available evidence provides a comprehensive understanding of the underlying genetic, environmental, molecular and physiological factors. However, there is still a relative paucity of evidence concerning its etiology and course.

This is mainly due to its complexity and the logistical challenges involved in investigating psychotic symptoms experienced by patients. Historically, the pathophysiology of schizophrenia

Krzysztof Rudkowski, Jerzy Samochowiec, Aleksandra Mazur, Jolanta Kucharska-Mazur: Department of Psychiatry of the Pomeranian Medical University in Szczecin

Correspondence address: krudkowski@gmail.com

was associated with abnormal neurological development and abnormal activity of the dopaminergic pathways [4]. While the dopamine hypothesis has been accepted as one of the most likely theories explaining the causes of schizophrenia for years, many recent studies tend to shift their focus towards the relationship between the central nervous system function and processes occurring in other regions of the organism. More and more researchers notice the links between the mental state and the immune system, emphasizing the role of inflammatory processes in the etiopathogenesis of psychotic symptoms [5, 6]. As early as in the 1980s, the immune hypothesis was formulated, which assumes that disorders of the immune system and subsequent inflammation within the nervous system lead to progressive brain changes in patients with schizophrenia [7,8]. The aim of this paper is to review available evidence suggesting the involvement of inflammatory processes in the pathogenesis of schizophrenia and to discuss its potential underlying mechanisms.

THE ROLE OF INFLAMMATION IN THE COURSE OF SCHIZOPHRENIA

Inflammation is a complex biological process activated by various innocuous stimuli. The presence of a noxious agent stimulates the response of the immune system to protect the body from such threats, minimize the risk of tissue damage and prevent systemic destabilization. In the case of an acute phase of inflammation, i.e. a physical injury or infection, typical symptoms of heat, pain, redness, or swelling appear [9]. When the harmful stimulus is neutralized, the acute inflammatory process tends to subside. There is, however, evidence of chronic inflammatory processes and continuous stimulation of the immune system in people with schizophrenia. The activation of the immune system can be measured by determining the level of cytokines, which are proteins modulating and influencing the inflammation process. Many of them have been tested as potential biomarkers of schizophrenia. For example, the levels of classical pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α) are visibly elevated in patients with acute psychoses

[10]. Interestingly, interleukin-12 (IL-12), gamma interferon (INF- γ) and TNF - α are raised not only during acute psychotic relapses but also in chronic presentations of schizophrenia [11]. Similar observations have been made in previously untreated patients with first-episode psychosis (FEP) [6] and those at a clinically high risk of developing psychosis [12], which may suggest that the generalized inflammation precedes the onset and development of overt psychotic symptoms. Unfortunately, most studies on inflammatory biomarkers in psychosis are cross-sectional, which makes it impossible to establish the cause and effect relationship between exposure (inflammation) and outcome (psychosis). Longitudinal studies are helpful in this case. Khandaker et al. demonstrated that elevated serum IL-6 levels in children aged 9 were associated with an increased risk of psychotic disorders at the age of 18 [13]. In addition, Metcalf et al. [14] observed that elevated levels of C-reactive protein (CRP) at the age of 15 were associated with an increased risk of developing schizophrenia at the age of 27. Without doubt, any definitive conclusions concerning this matter require further research. However, available findings seem to support the notion that inflammation does indeed increase the risk of psychosis.

Tests of inflammatory biomarkers do not only offer a diagnostic value, but they can also be useful for prognostic purposes, to assess the effectiveness of treatment. There are reports that treatment-resistant patients have elevated levels of sTNFR1 [15], IL-2 [16], IL-6 [17], IL-8 and IL-10 [18]. In patients with first episode psychosis who did not respond to conventional antipsychotic treatment, elevated levels of IL-6 and INF- γ were observed both at baseline and after 12 weeks of observation, while in treatment responders, they returned to normal [19]. These findings seem particularly relevant for those patients who do not respond optimally to traditional treatments, but may benefit from therapies targeting other biological pathways, such as anti-inflammatory or immunomodulatory agents.

OXIDISING AND ANTIOXIDISING AGENTS

The concept of oxidative stress (OxS) is closely linked to the inflammatory theory of schiz-

ophrenia. Oxidative/nitrosative stress (O&NS) was first described as an imbalance between oxidants and antioxidants in favor of oxidants, potentially leading to damage at an oxidant/antioxidant ratio >1 [20]. Thus, O&NS is the result of a "lost battle" between the components necessary to combat pathogens and the mechanisms for their detoxification. Some by-products of mitochondrial function used to kill pathogens or foreign cells are free radicals (compounds with unpaired electrons, making them highly reactive). Most of them react immediately with other particles. These are mainly reactive oxygen species (ROS) or reactive nitrogen species (RNS). In moderate concentrations, free radicals play an important role as regulatory mediators in signaling processes such as regulation of vascular tension, platelet adhesion, oxidative phosphorylation and erythropoietin production and signal transduction from membrane receptors [21]. ROS can be released from damaged tissue, serving as inflammatory and immunological activators [22]. In addition, immune cells such as macrophages and microglia produce and use ROS to kill pathogens [23,24]. Thus, oxidative stress can be both an inductor and a product of inflammation.

The antioxidant system, responsible for carrying out free oxygen radicals into their inactive forms, is composed of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (Gpx) and glutathione reductase (GR). Non-enzymatic antioxidants include glutathione, albumin and vitamins A, E and C. Abnormal antioxidant levels and signs of oxidative stress in both peripheral [25-27] and nervous tissue [28, 29] of patients with schizophrenia have been identified in many studies. A recent meta-analysis of 44 studies showed decreased blood serum levels of antioxidant markers in patients with first episode psychosis and acute relapses of schizophrenia, which increased during antipsychotic treatment [26]. In another study, however, a decrease in superoxide dismutase activity (SOD) in blood serum and cerebrospinal fluid was described in patients experiencing the first episode of schizophrenia [30]. A recent meta-analysis of FEP studies showed similar findings of reduced total antioxidant status in patients with the first episode of psychosis compared to the control group [31]. Thus, psychotic disorders are characterized by

an oxidative-antioxidative imbalance due to the exhaustion of antioxidant compensation mechanisms. Pro-oxidant factors contribute to protein, lipid or DNA damage and may become potential biomarkers of schizophrenia [32]. However, the question whether oxidative stress is the cause or rather the effect of inflammatory processes in the course of schizophrenia remains unresolved. Despite the lack of a clear answer, findings to date lay the grounds for new treatments with antioxidant substances and agents such as N-acetylcysteine [33] or polyunsaturated fatty acids [34].

POTENTIAL SOURCES OF INFLAMMATION

Although there seems to be a consensus that factors associated with the inflammatory process coexist with the diagnosis of schizophrenia, the question arises as to the origins of this relationship. While the answer to this question remains unclear, it is known that the process is multidimensional.

Patients with schizophrenia may have a genetic predisposition to increased inflammatory activity. Genome-wide association studies allow identification of genetic polymorphisms that may cause genetic susceptibility to infection [35]. Such studies indicate that the main tissue compatibility system on chromosome 6p, known for its key role in the mechanisms of immune response, is an important polymorphic region (single nucleotide polymorphism, SNP) in patients with schizophrenia [36, 37]. The most important investigated associations concern the HLA system genes that modulate inflammatory response [38], peptide genes involved in antimicrobial defense against pathogens [39] and genes potentially involved in DNA repair and methylation [40, 41]. It appears that the risk of schizophrenia is particularly associated with a mutation of the 4A complement coding gene (C4A) [41]. What is more, several SNPs have been identified to play an important role in inflammatory and immunological processes in schizophrenia patients [42]. For years, schizophrenia had been considered a heterogeneous disease. In 1988 Carpenter et al. [43] developed the concept of deficit schizophrenia describing patients with primary and permanent negative symptoms. Despite a relatively small number of studies in this subgroup

of patients, there are indications that polymorphisms of immune response genes may also affect the onset and presentation of the deficit syndrome. Findings suggest that polymorphism of CD28 protein may affect the risk of deficit schizophrenia [44].

According to epidemiological studies, there is a link between prenatal exposure to pathogens and the onset of schizophrenia. Pregnancy is a period in which the mother is more susceptible to infections and increased pro-inflammatory cytokine levels. The increased incidence of influenza and exposure to infection from winter to spring increases the risk of having offspring that will develop schizophrenia in the future [45]. Respiratory [46, 47] and reproductive [46, 48] infections during pregnancy are also associated with an increased incidence of schizophrenia in the offspring. Other pathogens potentially associated with schizophrenia include maternal infection with *T. gondii* [49], rubella [50], measles [51], polio [52] and type 2 herpes [52]. Activation of the maternal immune system, probably in combination with other factors, may affect the process by which prenatal exposure to infections leads to an increased risk of neuropsychiatric disorders in the child [53]. Evidence to support this hypothesis also comes from numerous animal studies [54, 55]. For example, in mice, exposure of the mother to lipopolysaccharide, which induces an immune response, increased anxiety and reduced social interaction in her offspring [56].

There is a confirmed link between childhood trauma and increased risk of psychosis [57-59]. Incidentally, it is also significantly linked with the severity of positive symptoms in people with psychotic disorders [60]. There is evidence of increased baseline inflammation in adults with a history of childhood trauma. A recent meta-analysis found significantly higher levels of CRP, TNF- α and IL-6 in adults who were abused as children [61]. Interestingly, another study found that TNF- α levels are related to the severity of childhood trauma. Chronic inflammation seems to be a common biological mechanism underlying both trauma and psychosis. Early childhood trauma leads to dysregulation of the immune system, resulting in the development of a specific hypersensitivity, which leads to the development of a pro-inflammatory phenotype [62].

Another evidence of the relationship between the immune system and the stress response was a study on mice where prenatal immune activation was followed by exposure to stress during puberty. In mice exposed to both, elevated levels of neuroinflammatory markers were observed, including increased activation of the microglia during adolescence. It may therefore suggest that prenatal immune activation results in increased susceptibility to harmful effects of stress [55].

Numerous studies on the effect of gastrointestinal and microbial functioning on the pathogenesis of schizophrenia are currently underway [63]. For example, coeliac disease, an autoimmune disease affecting gastrointestinal function, is associated with an increased risk of schizophrenia [64]. The intestines, together with their bacterial flora and the central nervous system, are closely connected through the brain-gut microbiota axis. This is a two-way communication pathway, involving both neural and immune mechanisms [65]. Gut microbiota has been shown to play an important role in brain development, specifically in the formation and maturation of nerve synapses [66]. Hypotheses that schizophrenia has its source in the gastrointestinal tract appeared in the mid-20th century. The Buscaino post-mortem study on patients with schizophrenia [67] revealed numerous inflammatory changes within the gastrointestinal tract – in half of them it was gastritis, while in the majority of patients it was inflammation of the small or large intestine. It is now believed that increased intestinal permeability in patients without visible symptoms of gastrointestinal diseases, caused by factors such as stress or infection, allows the antigens to enter the portal circulation, triggering an inflammatory reaction – a process which is called bacterial translocation [68]. Elevated markers of bacterial translocation in plasma of patients with schizophrenia suggest the presence of microbial disturbances [69].

Other postulated sources of inflammatory processes in schizophrenia include obstetric complications [70], prenatal [71] and postnatal malnutrition [72] and use of psychoactive substances [73]. Inflammation in the course of schizophrenia does not have to be a response to infection. It may also be caused by disturbances in cell

homeostasis control processes. The immune response and inflammatory processes are not only stimulated by pathogens, but are also used as signals to maintain cell homeostasis in the nerve tissue. Therefore, blocking of NMDA receptors may cause oxidative stress in interneurons expressing parvalbumin, which is mediated by IL-6 [74]. Findings from post-mortem studies on patients with schizophrenia suggest the presence of damage to these neurons [75]. In fact, there is probably a certain constellation of genetic and environmental factors which, acting together, increase the risk of psychotic disorders in susceptible individuals, and this process can be at least in part modulated through inflammatory mechanisms.

MECHANISMS LINKING INFLAMMATORY PROCESSES AND PSYCHOSIS

Although there is evidence of a relationship between inflammatory processes and schizophrenia, the underlying mechanisms by which these processes can ultimately lead to the onset of psychotic symptoms are not fully understood. One of the proposed theories relates to the influence of cytokines on the kynurenine pathway. Pro-inflammatory cytokines such as IL-6 activate indoleamine 2,3-dioxygenase (IDO), an enzyme that breaks down tryptophan into potentially neurotoxic kynurenine metabolites such as kynurenic acid (KYNA) or quinoline acid (QA). Changes in the metabolism of the kynurenine pathway were found in the prefrontal cortex and cerebrospinal fluid of patients with schizophrenia [76-79]. Kynurenic acid is also an endogenous NMDA receptor antagonist and is involved in the functioning of mesocorticolimbic neurons, thus combining the dopamine hypothesis of schizophrenia with the concept of glutamergic transmission deficit [80].

The second proposed mechanism is related to the cascade of toll-like receptor proteins (TLRs), which are expressed in the cell membrane of cells of the congenital immune system, including macrophages [81]. Recognizing specific molecular structures that are components of pathogens, TLRs serve as the first-line defense against microbial invasion. Their activation leads to the activation of signal pathways and subsequent pro-

duction of pro-inflammatory molecules, including cytokines [82]. It has been shown that excessive activity of TLR-containing pathways can be associated with psychosis [83]. The TLR-induced release of IL-1 β , IL-6, IL-8 and TNF- α was significantly higher in schizophrenic patients to whose blood specific TLR agonists were added, compared to the control group [83]. In addition, post-mortem studies showed TLR4 over-expression in the brains of patients with schizophrenia [84], while in animal models TLR4 was associated with a neuroinflammatory process induced by bacterial translocation of intestinal flora [66]. It is now assumed that pathogenic molecules from maternal infections may be a source of activation of some TLRs [85].

Another mechanism linking inflammatory factors and psychosis is the concept of "sterile inflammation". There is evidence to suggest that chronic activation of complement cascade proteins directly triggers the inflammatory process within the brain, thus affecting its proper functioning [86]. This process is initiated by the presence of damage associated molecular patterns (DAMPs), which are recognized by the mannose binding lectin (MBL), activating the lectin pathway of the complement cascade [87].

THE BRAIN AND INFLAMMATORY PROCESSES

The brain is considered to be an 'immunologically privileged' organ, thanks, among other, to the presence of the blood-brain barrier (BBB), which is designed to protect the structures of the central nervous system from systemic infection. Numerous studies have distinguished immune signals by dividing them into innate immunity, in which monocytes and macrophages predominate, and acquired immunity, including cytokines and chemokines secreted from these cells [6, 88]. Cytokines and their receptors seem to be essential for growth, migration and survival of fetal neurons [89, 90]. In adults, apart from their immune function, cytokines play a signaling role and are an important link in the communication of astrocytes and glial cells [88].

It is difficult to unequivocally infer the presence of inflammatory processes in the CNS based only on increased levels of proinflammatory markers in peripheral blood. Nevertheless,

there is a lot of evidence for the presence of CNS inflammatory processes in the course of schizophrenia from cerebrospinal fluid (CSF) examinations. The results of a meta-analysis conducted in 2018 clearly indicate a significant increase in IL-6 and IL-8 levels in CSF of patients with schizophrenia relative to controls [91]. Although various inflammatory markers have been extensively analyzed, the most consistent data to date concern the increased CSF and IL-6 serum levels in patients with schizophrenia. Initially elevated levels of IL-6, IL-10 and TNF- α were recorded especially in medication-naive patients with first episode psychosis. Risperidone therapy resulted in reduced concentrations of all three cytokines to the levels appropriate for healthy individuals [92]. This seems particularly interesting because IL-6 is directly excreted from monocytes and constitutes the main component of the adaptive immune system [93].

The temporal and pathogenetic relationships between peripheral and central inflammatory processes in schizophrenia remain unclear. Cytokines are relatively large molecules that do not easily penetrate the undamaged BBB. Researchers highlight three pathways through which peripheral cytokines may affect the CNS. Firstly, pro-inflammatory cytokines can access the brain through the perivascular organs (i.e. the humoral pathway). Secondly, peripheral cytokines can stimulate the vagus nerve, leading to activation of the nucleus of the solitary band (i.e. the neural pathway). Finally, cytokines can stimulate the microglia to recruit monocytes (i.e. the cellular pathway) [94]. Regardless, damages to the barrier itself seem to occur in the very course of psychosis. Indeed, ultrastructural abnormalities and increased BBB permeability were observed in patients with schizophrenia [95, 96]. In addition, the results of a meta-analysis of case-control studies [97] indicate 76% higher serum levels of S100 calcium-binding protein B (S100B), considered a marker of brain damage and BBB dysfunction, in patients with schizophrenia compared to the control group. Pollak et al. [98] analyzed evidence of BBB dysfunction from cerebrospinal fluid, post-mortem and neuroimaging studies, observing an increased permeability of BBB in psychosis, which is a credible mechanism by which pro-inflammatory cytokines from the peripheral regions

can penetrate BBB and directly affect inflammation in the CNS.

Another important element of the mechanism explaining the formation of inflammatory processes in the central nervous system is the function of microglia cells. They are the cerebral equivalent of macrophages, and one of their main roles is to defend the CNS. The microglia cells are considered the most sensitive "sensors" in the brain. When a pathogen is detected, they undergo a complex, multi-stage process called microglia activation [99]. Activated microglia produces, among others, prostaglandins, chemokines, cytokines, complement proteins or proteinases, whose long-term activity, by increasing oxidative stress and activating cell death trails, can have harmful effects on sensitive cell populations [100]. There is evidence of increased activation of microglia in the course of schizophrenia. Neuroimaging with positron emission tomography has shown the activation of microglia in patients with diagnosed schizophrenia as well as in individuals at high risk of psychosis [101]. A meta-analysis of post-mortem studies [102] revealed a significant increase in the microglia density in the brains of patients with schizophrenia compared to healthy individuals. Interestingly, findings suggest that the activation of microglia can be inhibited by atypical neuroleptics such as olanzapine, risperidone or ziprasidone [103].

An important element as regards the effect of inflammatory processes on the functioning of the CNS is the complement system. This group of plasma proteins constituting the key element of innate immunity is activated in a cascade fashion by foreign or damaged cells in one of three ways (classical, alternative or lectin), ultimately leading to the formation of a complex attacking the membrane. The proteins of the complement system have several immune functions [104]. Abnormal activity of complement proteins is associated with numerous diseases such as systemic lupus erythematosus [105], epilepsy [106] and Alzheimer's disease [107]. Sekar et al. [41] demonstrated the relationship of allele genes encoding the 4A and 4B components of the complement system (C4A and C4B) with schizophrenia and increased expression of C4A mRNA in brain tissue of patients with schizophrenia. Another study showed differences in

complement component levels in patients with first episode psychosis and chronic schizophrenia. In patients with a long history of treatment, elevated levels of the C4 component were reported with decreased levels of the C3 component, while in patients with FEP both components were elevated [108]. It has also been shown that the C3a component may be a risk predictor and potential marker of FEP [109]

Therefore, abnormal activity of the complement system, disturbing pruning processes during significant developmental periods, may be considered an important element of the pathogenesis of schizophrenia [110].

SUPPORTIVE TREATMENTS

Given the above findings and the ever-growing evidence for understanding the role of inflammation in the course of psychosis, it can be concluded that some patients will benefit from therapies for inflammation. There are several classes of anti-inflammatory drugs with different mechanisms of action used in a number of inflammatory and immunological diseases. The most widely studied include non-steroidal anti-inflammatory drugs (NSAIDs), acetylcysteine (N-acetylcysteine, NAC), omega-3 fatty acids and statins. The use of some of them shows promise in the therapy of schizophrenia, mainly as an add-on to standard forms of treatment.

Non-steroidal anti-inflammatory drugs are a group of agents that affect inflammation by inhibiting the enzyme cyclooxygenase (COX), responsible for the production of pro-inflammatory prostaglandins [111]. The first and most widely used drug in this group is acetylsalicylic acid (ASA). In a double-blind study involving 70 patients with diagnosed schizophrenia, participants received aspirin or placebo in addition to standard antipsychotic therapy. Treatment with aspirin was associated with a small but significant decrease in the general and positive symptom PANSS scores [112].

N-acetylcysteine (NAC) is a precursor of glutathione and has antioxidant and anti-inflammatory properties resulting from inhibition of TNF- α , IL-1 β or IL-6 [113]. In a newly published study, patients who received additional NAC showed a significant improvement in the cate-

gory of positive, negative symptoms and general psychopathology measured by the PANSS scale, compared to patients receiving placebo [114]. In another 12-month study, combined therapy with NAC resulted in an improvement in disorganized thinking and general score, as well as negative symptoms subscale, measured by the PANSS scale, compared to placebo [115].

A growing body of evidence in the field of neurophysiology underlines the role of polyunsaturated fatty acids (PUFA) in the protection of nerve cells against oxidative damage. They also influence the control of inflammation, regulation of neurogenesis and preservation of neuronal function [116]. According to a meta-analysis of 68 randomized studies, omega-3 fatty acid supplementation led to a significant decrease in TNF- α , IL-6 and CRP levels in healthy individuals as well as in patients with chronic autoimmune and non-immune diseases [117]. In patients with chronic schizophrenia, the beneficial effect of omega-3 fatty acid supplementation on psychotic symptoms has not been demonstrated [118]. However, a beneficial effect compared to the placebo group was reported in FEP patients who received PUFA supplementation [119]. It seems, therefore, that the role of fatty acids is much more important in patients in the early stages of psychosis.

Statins are a group of drugs widely used in modern cardiology. Their action is based on inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA, hydroxy-methylglutaryl coenzyme A) – the enzyme responsible for the formation of endogenous cholesterol [120]. Apart from their hypolipidemic effect, they have a multidirectional role, inhibiting, among others, lipid oxidation or inflammatory reaction [121]. It has been shown that the administration of statins to patients with schizophrenia significantly improved their PANSS scores compared to the placebo group [122]. Given the increased risk of cardiovascular incidents in this patient population, statins may seem an attractive addition to standard therapy.

CONCLUSION

The immune system seems to be an important element in the pathogenesis of schizophrenia on

various neurobiological levels. Numerous epidemiological, biochemical or neuroimaging studies suggest the presence of elevated inflammatory markers in schizophrenia. This may occur in early stages of the disease, often preceding the onset of clinical symptoms. However, schizophrenia still remains one of the most mysterious diseases, and a great challenge to contemporary medicine. A translational approach, combining epidemiological, genetic, oxidative stress and clinical treatment concepts, has extended our understanding of the complex neuro-inflammatory processes associated with the onset and course of schizophrenia. Unfortunately, still little is known about the temporal relationship between inflammatory changes and its onset. Therefore, it seems that in order to thoroughly understand the role of the inflammatory process in the pathogenesis of schizophrenia, further research extending beyond the boundaries of classical psychiatry is necessary.

REFERENCES

1. WHO | The world health report 2001 – Mental Health: New Understanding, New Hope. WHO [Internet]. 2013 [cited 2019 Oct 10]
2. Touloupoulou T, Picchioni M, Mortensen PB, Petersen L. IQ, the Urban Environment, and Their Impact on Future Schizophrenia Risk in Men. *Schizophr Bull* [Internet]. 2017 Sep 1 [cited 2019 Oct 10];43(5):1056–1063.
3. Rössler W, Joachim Salize H, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. *Eur Neuropsychopharmacol* [Internet]. 2005 Aug [cited 2019 Oct 10];15(4):399–409.
4. Howes OD, Kapur S. The Dopamine Hypothesis of Schizophrenia: Version III—The Final Common Pathway. *Schizophr Bull* [Internet]. 2009 Mar 30 [cited 2019 Oct 10];35(3):549–562.
5. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. *Biol Psychiatry* [Internet]. 2008 Apr 15 [cited 2019 Oct 10];63(8):801–808.
6. Uptegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis. *Schizophr Res* [Internet]. 2014 May 1 [cited 2019 Oct 10];155(1–3):101–108.
7. Fudenberg HH, Whitten HD, Merler E, Farmati O. Is schizophrenia an immunologic receptor disorder? *Med Hypotheses* [Internet]. 1983 Sep 1 [cited 2019 Oct 11];12(1):85–93.
8. Stevens JR. Pathophysiology of schizophrenia. *Clin Neuropharmacol* [Internet]. 1983 Jun [cited 2019 Oct 11];6(2):77–90.
9. Scott A, Khan KM, Cook JL, Duronio V. What is “inflammation”? Are we ready to move beyond Celsius? *Br J Sports Med* [Internet]. 2004 Jun [cited 2019 Oct 11];38(3):248–249.
10. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol Psychiatry* [Internet]. 2016 [cited 2019 Oct 23];21(12):1696–1709.
11. Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. *Biol Psychiatry* [Internet]. 2013 May 15 [cited 2019 Oct 23];73(10):993–999.
12. Khoury R, Nasrallah HA. Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait? *Schizophr Res* [Internet]. 2018 [cited 2019 Oct 23];199:31–38.
13. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life a population-based longitudinal study. *JAMA Psychiatry*. 2014 Oct 1;71(10):1121–1128.
14. Metcalf SA, Jones PB, Nordstrom T, Timonen M, Mäki P, Miettunen J, et al. Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study. *Brain Behav Immun* [Internet]. 2017 Jan [cited 2019 Oct 23];59:253–259.
15. Noto C, Gadelha A, Belanger SI, Spindola LM, Rocha NP, de Miranda AS, et al. Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. *J Psychiatr Res*. 2013;47(4):467–471.
16. Tan Y, Li Y, Tan S, Wang Z, Yang F, De Cao B, et al. Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia. *Schizophr Res*. 2015 Dec 1;169(1–3):16–21.
17. Lin A, Kenis G, Bignotti S, Tura GJB, De Jong R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6. *Schizophr Res*. 1998 Jun 22;32(1):9–15.
18. Maes M, Bocchio Chiavetto L, Bignotti S, Battista Tura G-J, Pioli R, Boin F, et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. *Schizophr Res* [Internet]. 2002 Apr 1 [cited 2019 Nov 7];54(3):281–291.
19. Mondelli V, Ciufolini S, Murri MB, Bonaccorso S, Di Forti M, Giordano A, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. *Schizophr Bull*. 2015;41(5):1162–1170.
20. Sies H. Oxidative stress: Oxidants and antioxidants. Vol. 82, *Experimental Physiology*. Blackwell Publishing Ltd; 1997;82:291–299.
21. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Tesler J. Free radicals and antioxidants in normal physiological functions and human disease. Vol 39, *International Journal of Biochemistry and Cell Biology*. 2007;39:44–8.

22. Lugin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. *Biological Chemistry*. 2014; 395: 203–230.
23. Bordt EA, Polster BM. NADPH oxidase – and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: A Bipartisan affair? *Free Radical Biology and Medicine*. Elsevier Inc.; 2014; 76: 34–46.
24. Zhai Z, Gomez-Mejiba SE, Gimenez MS, Deterding LJ, Tomer KB, Mason RP, et al. Free radical-operated proteotoxic stress in macrophages primed with lipopolysaccharide. *Free Radic Biol Med*. 2012 Jul 1;53(1):172–181.
25. Gysin R, Kraftsik R, Boulat O, Bovet P, Conus P, Comte-Krieger E, et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in Schizophrenia. *Antioxidants Redox Signal*. 2011 Oct 1;15(7):2003–2010.
26. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. *Biol Psychiatry*. 2013 Sep 15;74(6):400–409.
27. Fournier M, Ferrari C, Baumann PS, Polari A, Monin A, Bellier-Teichmann T, et al. Impaired metabolic reactivity to oxidative stress in early psychosis patients. *Schizophr Bull*. 2014;40(5):973–983.
28. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JTJ, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: Evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry*. 2004;9(7):684–697.
29. O'Donnell P, Do KQ, Arango C. Oxidative/nitrosative stress in psychiatric disorders: Are we there yet? *Schizophr Bull*. 2014;40(5):960–962.
30. Coughlin JM, Ishizuka K, Kano SI, Edwards JA, Seifuddin FT, Shimano MA, et al. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. *Molecular Psychiatry*. 2013;18: 10–11.
31. Fraguas D, Díaz-Caneja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, et al. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. *Schizophr Bull*. 2019 Jun 18;45(4):742–751.
32. Bai Z Le, Li XS, Chen GY, Du Y, Wei ZX, Chen X, et al. Serum Oxidative Stress Marker Levels in Unmedicated and Medicated Patients with Schizophrenia. *J Mol Neurosci*. 2018 Nov 1;66(3):428–436.
33. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. *Trends in Pharmacological Sciences*. 2013; 34:167–177.
34. Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2013 214–223.
35. Drago A, Giegling I, Schäfer M, Hartmann AM, Konte B, Friedl M, et al. Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. *Pharmacogenomics*. 2014;24(6):314–319.
36. Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421–427.
37. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009 Aug 6;460(7256):748–752.
38. Fellerhoff B, Laumbacher B, Mueller N, Gu S, Wank R. Associations between Chlamydia infections, schizophrenia and risk of HLA-A10. *Mol Psychiatry*. 2007 Mar;12(3):264–272.
39. Kawasaki H, Iwamuro S. Potential roles of histones in host defense as antimicrobial agents. *Infect Disord Drug Targets [Internet]*. 2008 Sep [cited 2019 Nov 9];8(3):195–205.
40. Costa E, Chen Y, Dong E, Grayson DR, Kundakovic M, Maloku E, et al. GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability. *Expert Rev Neurother [Internet]*. 2009 Jan 9 [cited 2019 Nov 9];9(1):87–98.
41. Sekar A, Bialas AR, De Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. *Nature*. 2016 Feb 11;530(7589):177–183.
42. Birnbaum R, Weinberger DR. A Genetics Perspective on the Role of the (Neuro)Immune System in Schizophrenia. *Schizophr Res*. 2020 Mar;217:105–113.
43. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: The concept. *Am J Psychiatry*. 1988;145(5):578–583.
44. Mak M, Misiak B, Frydecka D, Pelka-Wysiecka J, Kucharska-Mazur J, Samochowiec A, et al. Polymorphisms in immune-inflammatory response genes and the risk of deficit schizophrenia. *Schizophr Res*. 2018 Mar 1;193:359–363.
45. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. *American Journal of Psychiatry*; 2010; 167:261–280.
46. Sørensen HJ, Mortensen EL, Reinisch JM, Mednick SA. Association between prenatal exposure to bacterial infection and risk of Schizophrenia. *Schizophr Bull*. 2009 May;35(3):631–637.
47. Seltzer JP, Frissen A, Lensvelt-Mulders G, Morgan VA. Schizophrenia and 1957 pandemic of influenza: Meta-analysis. *Schizophr Bull*. 2010 Mar;36(2):219–228.
48. Babulas V, Factor-Litvak P, Goetz R, Schaefer CA, Brown AS. Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. *Am J Psychiatry*. 2006;163(5):927–929.
49. Brown AS, Schaefer CA, Quesenberry CP, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. *Am J Psychiatry*. 2005 Apr;162(4):767–773.
50. Brown AS, Cohen P, Greenwald S, Susser E. Non-affective psychosis after prenatal exposure to rubella. *Am J Psychiatry*. 2000 Mar;157(3):438–443.

51. Torrey EF, Miller J, Rawlings R, Yolken RH. Seasonality of births in schizophrenia and bipolar disorder: A review of the literature. *Schizophrenia Research*. 1997; 28:1–38.
52. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. *Arch Gen Psychiatry*. 2001;58(11):1032–1037.
53. Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. *Science. American Association for the Advancement of Science*; 2016; 353: 772–777.
54. Farrelly L, Föcking M, Piontkewitz Y, Dicker P, English J, Wynne K, et al. Maternal immune activation induces changes in myelin and metabolic proteins, some of which can be prevented with risperidone in adolescence. *Dev Neurosci*. 2015 Feb 24;37(1):43–55.
55. Giovanoli S, Engler H, Engler A, Richetto J, Voget M, Willi R, et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. *Science. American Association for the Advancement of Science*; 2013; 339:1100–1102.
56. Hava G, Vered L, Yael M, Mordechai H, Mahoud H. Alterations in behavior in adult offspring mice following maternal inflammation during pregnancy. *Dev Psychobiol*. 2006 Mar;48(2):162–168.
57. Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, et al. Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prospective and cross-sectional cohort studies. *Schizophr Bull*. 2012 Jun;38(4):661–671.
58. Morgan C, Fisher H. Environment and schizophrenia: Environmental factors in schizophrenia: Childhood trauma – A critical review. *Schizophrenia Bulletin*. 2007;33: 3–10.
59. Read J, Van Os J, Morrison AP, Ross CA. Childhood trauma, psychosis and schizophrenia: A literature review with theoretical and clinical implications. *Acta Psychiatrica Scandinavica*. 2005;112:30–50.
60. Bailey T, Alvarez-Jimenez M, Garcia-Sanchez AM, Hulbert C, Barlow E, Bendall S. Childhood trauma is associated with severity of hallucinations and delusions in psychotic disorders: A systematic review and meta-analysis. *Schizophr Bull*. 2018;44(5):1111–1122.
61. Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: A meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor- α . *Mol Psychiatry*. 2016 May 1;21(5):642–649.
62. Cattaneo A, Macchi F, Plazzotta G, Veronica B, Bocchio-Chiavetto L, Riva MA, Pariante CM. Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis. *Front Cell Neurosci*. 2015 Mar 31;9:40.
63. Severance EG, Yolken RH, Eaton WW. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. *Schizophrenia Research. Elsevier B.V.* 2016;176:23–35.
64. Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, et al. Association of schizophrenia and autoimmune diseases: Linkage of Danish national registers. *Am J Psychiatry*. 2006 Mar;163(3):521–528.
65. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut- brain axis: Interactions between enteric microbiota, central and enteric nervous systems. *Ann Gastroenterol*. 2015;28(2):203–209.
66. Gárate I, Garcia-Bueno B, Madrigal JLM, Caso JR, Alou L, Gomez-Lus ML, et al. Stress-induced neuroinflammation: Role of the toll-like receptor-4 pathway. *Biol Psychiatry*. 2013 Jan 1;73(1):32–43.
67. Buscaino GA. The amino-hepato-entero-toxic theory of schizophrenia: an historical evaluation. In: *The Biological Basis of Schizophrenia*. Springer Netherlands; 1978. p. 45–54.
68. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. *Front Cell Neurosci*. 2015 Oct 14;9:392.
69. Severance EG, Gressitt KL, Stallings CR, Origoni AE, Khushalani S, Leweke FM, et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. *Schizophr Res*. 2013 Aug;148(1–3):130–137.
70. Mittal VA, Ellman LM, Cannon TD. Gene-environment interaction and covariation in schizophrenia: The role of obstetric complications. *Schizophrenia Bulletin*. 2008;34: 1083–1094. Shen Q, Li ZQ, Sun Y, Wang T, Wan CL, Li XW, Zhao XZ, Feng GY, Li Sh, St Clair D, He L, Yu L. The role of pro-inflammatory factors in mediating the effects on the fetus of prenatal undernutrition: implications for schizophrenia. *Schizophr Res*. 2008 Feb;99(1-3):48-55.
71. Shen Q, Li ZQ, Sun Y, Wang T, Wan CL, Li XW, Zhao XZ, Feng GY, Li Sh, St Clair D, He L, Yu L. The role of pro-inflammatory factors in mediating the effects on the fetus of prenatal undernutrition: implications for schizophrenia. *Schizophr Res*. 2008 Feb;99(1-3):48-55.
72. Radhakrishnan R, Kaser M, Guloksuz S. The Link between the Immune System, Environment, and Psychosis. *Schizophr Bull*. 2017 Jul 1;43(4):693–697.
73. Miller BJ, Buckley PF, McEvoy JP. Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. *Schizophr Res*. 2018 May 1;195:275–282.
74. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. *J Neurosci*. 2008 Dec 17;28(51):13957–66.
75. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Vol. 35, *Trends in Neurosciences*. 2012. p. 57–67.
76. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. *Biol Psychiatry*. 2001 Oct 1;50(7):521–530.
77. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindström LH, et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. *Schizophr Res*. 2005 Dec 15;80(2–3):315–322.

78. Sathyaikumar K V., Stachowski EK, Wonodi I, Roberts RC, Rassoulpour A, McMahon RP, et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. *Schizophr Bull.* 2011 Nov;37(6):1147–56.
79. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. *Schizophr Bull.* 2012 May;38(3):426–432.
80. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. *Physiol Behav.* 2007;92(1–2):203–9.
81. Medzhitov R. Toll-like receptors and innate immunity; *Nat Rev Immunol.* 2001;1:135–145
82. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell.* 2010 Mar 19;140(6):805–820.
83. McKernan DP, Dennison U, Gaszner G, Cryan JF, Dinan TG. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. *Transl Psychiatry.* 2011 Aug 30;1(8):e36.
84. MacDowell KS, Pinacho R, Leza JC, Costa J, Ramos B, Garcia-Bueno B. Differential regulation of the TLR4 signalling pathway in post-mortem prefrontal cortex and cerebellum in chronic schizophrenia: Relationship with SP transcription factors. *Prog Neuro-Psychopharmacology Biol Psychiatry.* 2017 Oct 3;79:481–392
85. Venkatasubramanian G, Debnath M. The TRIPS (Toll-like receptors in immuno-inflammatory pathogenesis) Hypothesis: A novel postulate to understand schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry.* 2013; 44: 301–311.
86. Sankowski R, Mader S, Valdés-Ferrer SI. Systemic inflammation and the brain: Novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. *Front Cell Neurosci.* 2015 Feb 2;9(FEB).
87. Ratajczak MZ, Pedziwiatr D, Cymer M, Kucia M, Kucharska-Mazur J, Samochowiec J. Sterile Inflammation of Brain, due to Activation of Innate Immunity, as a Culprit in Psychiatric Disorders. *Front Psychiatry.* 2018 Feb 28;9:60.
88. Müller N. Immunology of schizophrenia. *Neuroimmunomodulation.* 2014;21(2–3):109–116.
89. Bakhiet M, Mousa A, Seiger A, Andersson J. Constitutive and inflammatory induction of alpha and beta chemokines in human first trimester forebrain astrocytes and neurons. *Mol Immunol [Internet].* 2002 May [cited 2019 Nov 15];38(12–13):921–929.
90. Meyer U, Weiner I, McAlonan GM, Feldon J. The neuropathological contribution of prenatal inflammation to schizophrenia. *Expert Rev Neurother.* 2011 Jan;11(1):29–32.
91. Orlovska-Waast S, Köhler-Forsberg O, Brix SW, Nordentoft M, Kondziella D, Krogh J, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. *Molecular Psychiatry.* Nature Publishing Group; 2019;24:869–887.
92. Noto C, Ota VK, Gouveia ES, Rizzo LB, Spindola LMN, Honda PHS, et al. Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. *Int J Neuropsychopharmacol.* 2014 Jan 1;18(4):1–8.
93. Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM, et al. Inflammatory molecular signature associated with infectious agents in psychosis. *Schizophr Bull.* 2014;40(5):963–972.
94. Lucile Capuron, Miller AH. Immune System to Brain Signaling. *Pharmacol Ther.* 2011;130(2):226–238.
95. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. *BMC MedGenet.* 2005 Feb 11;6:7.
96. Uranova NA, Zimina IS, Vikhrevva O V., Krukov NO, Rachmanova VI, Orlovskaya DD. Ultrastructural damage of capillaries in the neocortex in schizophrenia. *World J Biol Psychiatry.* 2010;11(3):567–578.
97. Aleksovska K, Leoncini E, Bonassi S, Cesario A, Boccia S, Frustaci A. Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia. *PLoS One.* 2014 Sep 9;9(9):e106342.
98. Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The blood-brain barrier in psychosis. *Lancet Psychiatry.* 2018 Jan;5(1):79–92.
99. Helmut K, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. *Physiol Rev.* 2011 Apr;91(2):461–553.
100. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. *Prog Neuro-Psychopharmacology Biol Psychiatry.* 2013 Apr 5;42:115–121.
101. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: An [11C] PBR28 PET brain imaging study. *Am J Psychiatry.* 2016 Jan 1;173(1):44–52.
102. van Kesteren CF, Gremmels H, de Witte LD, Hol EM, Van Gool AR, Falkai PG, Kahn RS, Sommer IE. Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies. *Transl Psychiatry.* 2017 Mar 28;7(3):e1075.
103. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon- γ . *Prog Neuro-Psychopharmacology Biol Psychiatry.* 2008 Jan 1;32(1):42–48.
104. Sarma JV, Ward PA. Sarma, J. V. and Ward, P. A. (2011) 'The complement system', *Cell and Tissue Research.* Springer-Verlag, 343(1):227–235.
105. Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. *Curr Neuropsychopharmacol.* 2011 Sep;9(3):449–457.
106. Kopczyńska M, Zelek WM, Vespa S, Touchard S, Wardle M, Loveless S, et al. Complement system biomarkers in epilepsy. *Seizure.* 2018 Aug 1;60:1–7.
107. VanTallie TB. Alzheimer's disease: Innate immunity gone awry? *Metabolism.* 2017 Apr 1;69:S41–49.
108. Cropley V, Laskaris L, Zalesky A, Weickert CS, Biase MD, Chana G, Baune B, Bousman C, Nelson B, McGorry PD, Everall I, Pantelis C. 01.6. Increased complement factors c3 and c4 in schizophrenia and the early stages of psychosis: implications for clinical symptomatology and cortical thickness. *Schizophr Bull.* 2018 Apr;44(Suppl 1):S74.

109. Kucharska-Mazur J, Tarnowski M, Dołęgowska B, Budkowska M, Pędziwiatr D, Jabłoński M, et al. Novel evidence for enhanced stem cell trafficking in antipsychotic-naïve subjects during their first psychotic episode. *J Psychiatr Res* [Internet]. 2014 Feb [cited 2019 May 13];49:18–24.
110. Nimgaonkar VL, Prasad KM, Chowdari KV, Severance EG, Yolken RH. The complement system: a gateway to geneenvironment interactions in schizophrenia pathogenesis. *Mol Psychiatry*. 2017 Nov;22(11):1554-1561.
111. Cashman JN. The mechanisms of action of NSAIDs in analgesia. *Drugs*. 1996;52 Suppl 5:13-23.
112. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2010 May;71(5):520–527.
113. Palacio JR, Markert UR, Martínez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. *Inflamm Res* [Internet]. 2011;60(7):695–704.
114. Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. *Prog Neuro-Psychopharmacology Biol Psychiatry*. 2018 Mar 2;82:289–296.
115. Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiioun NF, et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. *Schizophr Res*. 2018 Sep 1;199:395–402.
116. Hashimoto M, Maekawa M, Katakura M, Hamazaki K, Matsuoka Y. Possibility of polyunsaturated fatty acids for the prevention and treatment of neuropsychiatric illnesses. *J Pharmacol Sci*. 2014;124(3):294-300.
117. Li K, Huang T, Zheng J, Wu K, Li D. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α : A meta-analysis. *PLoS One*. 2014 Feb 5;9(2).
118. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies. *J Clin Psychopharmacol*. 2012 Apr;32(2):179–185.
119. Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawelczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. *J Psychiatr Res*. 2016 Feb 1;73:34–44.
120. Smith M, Lee N, Haney E, Carson S, Helfand M. Drug class review HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin. *Oregon Heal Sci Univ* [Internet]. 2009 [cited 2019 Nov 20];5:8-18
121. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (Pleiotropic) effects of statins in the management of acute coronary syndromes. *Journal of the American College of Cardiology*. 2005;46:1425-1433.
122. Shen H, Li R, Yan R, Zhou X, Feng X, Zhao M, et al. Adjunctive therapy with statins in schizophrenia patients: A meta-analysis and implications. *Psychiatry Res*. 2018 Apr 1;262:84-93.

